Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359464 | 0.79 | ADRA1B (0.39) | ADRA1BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2308976 | 0.75 | USP2 (0.57) | CYP2D6 | |
| SCHEMBL2312275 | 0.72 | ADRA1B (0.42) | ADRA1BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2310052 | 0.72 | ADRA1B (0.40) | ADRA1BOPRM1OPRL1 | |
| SCHEMBL2313152 | 0.70 | CACNA2D1 (0.59) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2305958 | 0.70 | CACNA2D1 (0.59) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2312141 | 0.70 | SLC6A9 (0.52) | OPRM1OPRL1 | |
| SCHEMBL2357962 | 0.70 | DPP8 (0.43) | ADRA1BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2312417 | 0.69 | CACNA2D1 (0.57) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2306889 | 0.69 | CACNA2D1 (0.57) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | claimed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | claimed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | ADRA1B 43/4885OPRM1 431/4885OPRD1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.